CN Patent

CN114514018A — 包括质子泵抑制剂和抗酸剂的药物组合物

Assigned to Hanmi Pharmaceutical Co Ltd · Expires 2022-05-17 · 4y expired

What this patent protects

本发明一方面提供一种药物组合物和使用其的药物复合制剂，所述药物组合物包括质子泵抑制剂或其药学上可接受的盐；和选自氢氧化镁、氧化镁或其混合物的抗酸剂作为活性成分。

USPTO Abstract

本发明一方面提供一种药物组合物和使用其的药物复合制剂，所述药物组合物包括质子泵抑制剂或其药学上可接受的盐；和选自氢氧化镁、氧化镁或其混合物的抗酸剂作为活性成分。

Drugs covered by this patent

azilsartan-kamedoxomil (AZILSARTAN KAMEDOXOMIL)

Patent Metadata

Patent number: CN114514018A
Jurisdiction: CN
Classification: —
Expires: 2022-05-17
Drug substance claim: No
Drug product claim: No
Assignee: Hanmi Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.